Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences schedules two September 2026 investor conference presentations to discuss its CNS-focused drug development pipeline.

Rhea-AI Summary

Bright Minds Biosciences (DRUG) will present at two investor conferences in September 2026. Management is scheduled to participate in the Cantor Global Healthcare Conference on September 9, 2026 at 1:35 p.m. ET and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 at 4:00 p.m. ET.

Market Context

The earlier Jefferies presentation notice was followed by 0.88% over 24 hours, providing a directly ...

Analysis

The earlier Jefferies presentation notice was followed by 0.88% over 24 hours, providing a directly comparable precedent. Conference disclosures remain the key item to watch, alongside moderate short positioning as a volatility risk.

Key Figures

Cantor conference date: September 9, 2026 Cantor presentation time: 1:35pm ET H.C. Wainwright conference date: September 15, 2026 +1 more

4 metrics

Cantor conference date September 9, 2026 Cantor Global Healthcare Conference 2026

Cantor presentation time 1:35pm ET September 9, 2026 presentation

H.C. Wainwright conference date September 15, 2026 H.C. Wainwright 28th Annual Global Investment Conference

H.C. Wainwright presentation time 4:00pm ET September 15, 2026 presentation

Historical Context

2 past events · Latest: May 26 (Neutral)

Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 26	Conference presentation	Neutral	+0.9%	Jefferies conference presentation announcement was followed by a 0.88% 24-hour gain.
Jul 31	Board appointment	Neutral	-1.8%	Neuroscience executive joined Vistagen’s board; Bright Minds was referenced in the announcement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior presentation announcement was followed by a 0.88% gain, while a management appointment was followed by a 1.84% decline; the limited history shows no consistent direction.

Key Terms

5-HT2 agonists, CNS, serotonergic agonists, NCE programs

4 terms

5-HT2 agonists medical

"focused on developing highly selective 5-HT2 agonists for the treatment"

Drugs described as 5-HT2 agonists are medicines that act like a key fitting into a specific serotonin receptor (the 5-HT2 family) to switch that receptor on. Investors care because turning these receptors on can produce therapeutic effects (for conditions like mood, appetite or sleep) but also carries distinct safety and regulatory risks tied to which 5-HT2 subtype is affected, so trial results and approvals can strongly move a company’s value.

CNS medical

"depression, and other central nervous system (CNS) disorders"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

serotonergic agonists medical

"a unique platform of highly selective serotonergic agonists"

Serotonergic agonists are drugs or compounds that activate the brain’s serotonin receptors, acting like keys that turn on specific cellular “locks” involved in mood, sleep, pain, and other bodily functions. Investors watch them because their ability to treat common or hard-to-treat conditions can create large markets, raise regulatory and safety questions, and affect a drug maker’s revenue and valuation depending on clinical trial results, approvals, patents and side-effect profiles.

NCE programs technical

"This has provided a rich portfolio of NCE programs within neurology"

Programs to discover, develop and seek regulatory approval for a new chemical entity (NCE), meaning a drug whose active ingredient has never before been approved. These programs cover laboratory research, clinical trials and regulatory filings; success can create a product with first-in-class status, patent protection and temporary marketing exclusivity, which can materially change a drug maker’s future revenue. Think of an NCE program as creating an original product that can open a new revenue stream if regulators agree it is safe and effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

	EVENT:	Cantor Global Healthcare Conference 2026
	DATE:	Wednesday, September 9, 2026
	TIME:	1:35pm ET
	EVENT:	H.C. Wainwright 28th Annual Global Investment Conference
	DATE:	Tuesday, September 15, 2026
	TIME:	4:00pm ET

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com

FAQ

When will Bright Minds Biosciences (DRUG) present at the Cantor Global Healthcare Conference 2026?

Bright Minds Biosciences is scheduled to present at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, at 1:35 p.m. ET. The company plans to discuss its activities in CNS-focused drug development.

What is the date and time of Bright Minds Biosciences (DRUG) presentation at the H.C. Wainwright 28th Annual Global Investment Conference?

The company is due to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 4:00 p.m. ET, offering investors an update on its business and development programs.

What therapeutic areas does Bright Minds Biosciences (DRUG) focus on?

Bright Minds Biosciences focuses on developing highly selective 5-HT2 agonists and other serotonergic compounds for conditions such as drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system disorders.